Skip to content

Omeros OMER Accounts Receivable

Accounts Receivable at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.23M+23.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.75M+44.0%
Janux Therapeutics logo
Janux TherapeuticsJANX
$35M
Johnson & Johnson logo
Johnson & JohnsonJNJ
$17.72B+10.6%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$48.32M+10.9%
Opko Health logo
Opko HealthOPK
$79.64M-17.2%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's accounts receivable?
Omeros (OMER) reported accounts receivable of $12.03M in Q1 2026.
How has Omeros's accounts receivable changed year-over-year?
Omeros's accounts receivable increased by 70.0% year-over-year, from $7.08M to $12.03M.
What is the long-term trend for Omeros's accounts receivable?
Over 5 years (2020 to 2025), Omeros's accounts receivable has grown at a 23.2% compound annual growth rate (CAGR), from $3.84M to $10.92M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.